Early Access — free while we kick the tires
EdgarHawk

PRQR ProQR Therapeutics N.V. Insider Trading

Latest: Director Bought $231K of Shares · Jun 2026
1 filing analyzed · Latest 2026-06-30

Get alerts for PRQR

Add PRQR to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Insider buys
1
Insider sells
0
Unique insiders
1
Direction
Net buying

Historically, medium-priority insider buys have outperformed the S&P 500 by a median ~1% over the 30 days after filing — the edge is concentrated in that first month (n ≈ 7,520, 2022-2026). Past results don't predict the future. How we measure this ↗

June 2026
2026-06-30
medium
150,000 shares
$231,000
@ $1.54
Significance 6/10

Director Bart Filius purchases 150,000 shares of PRQR at $1.54; stock now at $1.86, up 17.7% in 30 days

Bart Filius, a director, purchased 150,000 shares at $1.54 for $231,000.00 on 2026-06-26, establishing an initial position in the company. The current price of $1.86 represents a gain from the transaction price, and the stock has risen 17.7% over the past 30 days and 8.8% over 90 days, reflecting positive recent momentum. However, the stock remains -40.0% below its 52-week high of $3.10, placing this purchase well within a significantly depressed valuation window relative to recent history. This director's initiation of a material holding during a period of downside recovery warrants monitoring of whether this accumulation reflects broader board-level conviction in the company's turnaround trajectory.